Published on June 23, 2012 at 1:34 AM
Repligen Corporation (NASDAQ:RGEN) today announced that it has received
a Complete Response Letter (CRL) from the U.S. Food & Drug
Administration (FDA) regarding the Company's New Drug Application (NDA)
for RG1068 (synthetic human secretin). RG1068 was evaluated in a Phase 3
study to improve detection of pancreatic duct abnormalities in
combination with MRI in patients with known or suspected pancreatitis.
The CRL indicates that the FDA has completed its review of the RG1068
NDA and has determined that additional clinical efficacy and safety
trial data will be required to support potential approval of the NDA.
There were no specific safety concerns cited in the CRL, although safety
will continue to be monitored in conjunction with any future clinical
trial. No deficiencies were cited in the CRL with respect to the
manufacturing, pharmacology or toxicology sections of the NDA.
"We will continue to engage in dialogue with the FDA to determine the
design and scope of a clinical program that will address the agency's
requirements for approval of RG1068," said Walter C. Herlihy, Ph.D.,
President and Chief Executive Officer of Repligen. "We believe that
RG1068, if approved, will provide a safe and effective means to
non-invasively image the pancreas with MRI and will meet an important
unmet medical need for patients with pancreatitis."
Repligen filed its NDA for RG1068 on December 21, 2011 based on the
re-read of Phase 3 clinical trial data. On February 21, 2012, the FDA
accepted the NDA filing and granted it priority review based on its
prior Fast Track designation. In addition, on March 5, 2012, Repligen
submitted a Marketing Authorization Application (MAA) to the European
Medicines Agency (EMA) that was successfully validated for full review
by the EMA's Committee for Medicinal Products for Human Use.
Source: Repligen Corporation